U.S. Stock Market - U.S. stocks traded mixed, with the Nasdaq gaining over 100 points, while the Dow decreased by 0.57% to 44,204.33 and the S&P 500 rose by 0.01% to 6,269.15 [1] - Information technology shares increased by 1.6%, while materials stocks dipped by 0.9% [1] Wells Fargo Financial Results - Wells Fargo reported adjusted earnings of $1.54 per share, exceeding market estimates of $1.40 per share [2] - The company reported net interest income of $11.71 billion, down 2% year over year for Q2 2025 [2] Commodity Market - Oil prices fell by 0.5% to $66.66, gold decreased by 0.1% to $3,355.90, silver dropped by 1.2% to $38.280, and copper fell by 0.3% to $5.5320 [5] European Market Performance - European shares were lower, with the eurozone's STOXX 600 slipping by 0.09% and Spain's IBEX 35 Index falling by 1.16% [6] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei gaining 0.55% and Hong Kong's Hang Seng rising by 1.60%, while China's Shanghai Composite fell by 0.42% [7] Notable Stock Movements - Longevity Health Holdings, Inc. shares surged by 143% to $6.43 after a merger announcement [9] - Kairos Pharma, Ltd. shares increased by 87% to $1.2808 following positive trial results [9] - BloomZ Inc. shares rose by 57% to $0.2366 due to a partnership announcement [9] - Ryvyl Inc. shares dropped by 45% to $0.3552 after announcing a $6 million offering [9] - Rani Therapeutics Holdings, Inc. shares fell by 42% to $0.4058 after a direct offering announcement [9] - Simulations Plus, Inc. shares decreased by 19% to $14.15 following disappointing quarterly sales and a downgrade from Keybanc [9] Economic Indicator - The New York Empire State Manufacturing Index increased to 5.5 in July, compared to -16.0 in June, surpassing market estimates of -9.0 [10]

Core Viewpoint - Longevity Health Holdings, Inc. has announced a merger with 20/20 BioLabs, Inc. in an all-stock transaction aimed at enhancing its diagnostics capabilities and addressing chronic disease risks in America [1][4]. Company Overview - Longevity Health Holdings focuses on human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][10]. - 20/20 BioLabs specializes in laboratory tests for early detection and management of chronic disease risk, offering the only multi-cancer early detection blood test available for under $200 [9][10]. Merger Details - The merger is expected to close in the third quarter of 2025, pending customary closing conditions and stockholder approvals [7]. - Post-merger, 20/20 stockholders will own approximately 50.1% and Longevity stockholders will own approximately 49.9% of the combined company [7]. - The combined company will continue trading on Nasdaq under the symbol "XAGE" [1]. Financial Implications - The merger is projected to double Longevity's fiscal year 2025 revenue forecast from approximately $3-4 million to approximately $7-8 million [6][7]. - The combined company is expected to have a post-merger equity valuation of approximately $99 million, with 20/20's pre-money valuation at around $50 million [6][7]. - Anticipated operational savings and synergies are expected to exceed $1 million in fiscal year 2025 [6]. Strategic Goals - The merger aligns with Longevity's strategy to expand its footprint in diagnostics and enhance synergies with its existing product portfolio [1][4]. - The combined company aims to address the epidemic of chronic disease in America under the "Healthy Aging, Inside and Out™" initiative [1]. Management Structure - The management team of the combined company will be mutually selected, with a Board of Directors comprising three members from each company [8].